Dallas-based predictive AI company Spectral AI Inc. announced that company founder Dr. J. Michael DiMaio is returning to the company to serve as its board chairman.
Spectral AI, which focuses on medical diagnostics for treatment decisions in wound care with an AI-enhanced technology called DeepView, also announced a reorganization of its day-to-day operational responsibilities.
“Our board of directors welcomes Dr. DiMaio back to the role of Spectral AI’s chairman,” Richard Cotton, the current board chair, said in a statement. “Given our needs for the future, the board concluded it was clear Dr. DiMaio’s expertise, leadership style, and deep understanding of our industry and the DeepView System, paired with his deep commitment to patient care and our employees, make him the right person to lead Spectral AI’s next stage of growth. I look forward to supporting him and the rest of the board as they seize the opportunities ahead.”
Cotton will remain on the board and serve as head of the company’s audit committee and as its lead independent director.
DiMaio, who has more than 30 years of experience in cardiothoracic surgery, founded Spectral AI in 2009 and served as its CEO and chairman from 2011 to 2020. He currently holds a chief of staff post at Dallas-based Baylor Scott & White, where he oversees more than 650 physicians.
DiMaio said he was looking forward to resuming work with Spectral AI because of its potential to help patients.
“As a surgeon, my passion has always been to improve patient outcomes by providing clinicians with the most advanced tools for faster, more accurate diagnoses,” he said in a statement. “Spectral AI’s technology has the potential to revolutionize wound care, enabling healthcare providers to make critical decisions faster and with greater precision.”
Announcing a new Office of the Chairman
Spectral AI also announced that its board has authorized creation of an Office of the Chairman.
The new position will assume the company’s day-to-day operational responsibilities and support the ongoing clinical development and commercialization of Spectral AI’s DeepView System, with particular focus on engagement with the Biomedical Advanced Research and Development Authority (or BARDA), the FDA, commercialization efforts, and strategic relationships.
The Office of the Chairman, which will report directly to the board, will consist of CFO and General Counsel Vincent Capone, Chief Commercialization Officer Jeremiah Sparks, Interim Chief Operating Officer Stan Micek, and General Manager Louis Percoco.
The company said that in connection with the formation of the Office of the Chairman, Peter Carlson will be transitioning out of his role as CEO and leave the Spectral AI board to pursue other business opportunities. He will remain as a consultant to the company.
Get on the list.
Dallas Innovates, every day.
Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.